STEM CELL THERAPEUTIC

MEDIPOST Obtains Patent for its ‘CARTISTEM’ Production Technology’ in Six European Countries

MEDIPOST Obtains Patent for Core Alzheimer’s Disease Treatment Technology in Six European Countries

MEDIPOST Obtains Patent for Commercializing High-efficiency Technology to Culture Stem Cell

MEDIPOST Obtains Patent in Canada for its Stem Cell-based Alzheimer’s Disease Treatment Composition

MEDIPOST Obtains Patent for its High-Efficient Technology for Culturing Stem Cells

MEDIPOST Obtains Patent in UK for its Alzheimer’s Disease Treatment Technique that Uses Stem Cells

MEDIPOST Begins Sales of its Stem Cell Drug, ‘CARTISTEM’

Chinese Securities Company Praises MEDIPOST as a “Company with Most Profitable Stem Cell Drug”

MEDIPOST’s Stem Cell Drug ‘CARTISTEM’ Hits 5,000 Sales Mark

MEDIPOST Obtains Patent in US for its Next-Generation Stem Cell Culturing Technology

MEDIPOST Signs MOU with Canadian Public-Private Consortium Funded by the Government of Canada

MEDIPOST Obtains Patent in China for Its Brain Disease Treatment Technology that Uses Stem Cells